Bariatric surgery compared with GLP-1 receptor agonists: durability of weight loss and control of comorbidities

Abstract

The expanding efficacy of incretin-based pharmacotherapy has changed the comparison between metabolic and bariatric surgery and medical obesity treatment. This narrative critical review examines weight-loss durability, control of obesity-related complications, comparative evidence, and treatment selection using clinical trials, long-term surgical studies, contemporary guidelines, and comparative observational research identified through October 2026. Liraglutide, semaglutide, and tirzepatide produce different mean weight reductions, and outcomes also vary with dose, diabetes status, treatment exposure, and trial estimand. Continued pharmacotherapy can sustain substantial weight loss, whereas withdrawal trials demonstrate considerable regain. Surgery has longer follow-up and generally larger weight reductions in current comparative cohorts, but postoperative regain, diabetes relapse, nutritional deficiencies, and procedural complications remain clinically relevant. Semaglutide has demonstrated cardiovascular event reduction in a defined secondary-prevention population, while tirzepatide has disease-specific evidence in obesity-related heart failure and obstructive sleep apnea. These findings cannot be generalized indiscriminately across medications or equated with surgical remission outcomes. Direct contemporary comparisons remain predominantly observational; indirect randomized comparisons depend on uncertain comparability between trials. Treatment choice should therefore integrate required weight reduction, complication-specific evidence, operative risk, tolerability, access, and willingness to sustain follow-up. Sequential use of surgery and pharmacotherapy is a rational option supported by emerging evidence.